Member Info for Teamhanz

Hi MrMarkyMark, That is brilliant, thanks for sharing the link. Makes for great reading, plus very interesting point with regards to 301 nearing completion as that hasn't been said before. Very interesting indeed. ATB. Well, after all, it is the 5th of November. Sounds like we could be getting some fireworks after all!

401 results were ages ago. https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&cad=rja&uact=8&ved=2ahUKEwiP_Irg6ObsAhUKAcAKHTLXCaYQFjAGegQIAhAC&url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2Fresults%2FNCT02875340&usg=AOvVaw3GyytqUZljzZTtdBulrNML

We are waiting to hear more about funding/partnering for the next stage which has been ongoing forever.

Thanks for your response Nick. ATB.

Nick, is what Jason Pugh on ADVFN about you is the case?

101 was linked with GeneICE which has been terminated.

October Q&A just released on the companies website guys and gals

The Q&A very much anticipated now after the new website. All going in the right direction. Full results within 7 weeks too.

Wow, fancy new website for Valirx just come live. Looks very good.

Great post Adam. Thanks for your views and insight, greatly appreciated.

The lovely Suzy has just confirmed via email that the Q&A is only Schedule to be released before month end. She really is such a great Director, always quick responses and a pleasure to communicate with.

Its like the Mary Celeste here! Its going to feel like a very long wait until full results... A Nice progress update RNS on all our product line would do the power of good, but feel there probably isn't much else She can add on all fronts. So we wait.....

Seems someone has copied my handle and added a number at the end and seems to be tearing into one of the BB members over on ADVFN...Very scrappy over on that board. Think ill stick to LSE ha.

Morning Stumbler. It was a questions from an investor on the last Q&A and Dr Suzy's answer followed -

It would be great if you could please provide some details and thoughts specifically on the future of
VAL 201 to accompany the results release which I understand will be published before the end of Q3
2020?

Now that we have the headline results from the VAL201 clinical trial, we will be providing updates to our
industry contacts and taking a decision on the best route forward for further development of VAL201.
All possibilities will be explored with potential partners, including Joint Venture arrangements, which
could see a partner funding a larger trial in a ValiRx subsidiary; out-licensing, which could see ValiRx
receive a combination of upfront, milestone and royalty payments; or an outright sale, which would see
a one-off payment to ValiRx.

The thing is they have specifically professed that the new direction of the company will be in earlier stages now, i think 401 was a different case as much more niche product to off load. If this is the route for 201 it kind of contradicts the new Valirx model going forward. I there for see this being out licensed or sold. Any other views on this?

To add to that i certainly hope it isn't black cat 401 style 'deal'. I hope it is either out licensing or an outright sale so we can finally get decent money coming in to stop the dilution approach!

Interesting reading through the Q&A thoroughly again. So this question was Put to Suzy, her response is very interesting as from this response i take it we may find out the deal with 201 on arrival of the Full results as she will be discussing the next stage with just the headline results in tow. Very interesting. Would be amazing if the Japanese company was the main leader for 301 AND 201. -

It would be great if you could please provide some details and thoughts specifically on the future of
VAL 201 to accompany the results release which I understand will be published before the end of Q3
2020.
Now that we have the headline results from the VAL201 clinical trial, we will be providing updates to our
industry contacts and taking a decision on the best route forward for further development of VAL201.
All possibilities will be explored with potential partners, including Joint Venture arrangements, which
could see a partner funding a larger trial in a ValiRx subsidiary; out-licensing, which could see ValiRx
receive a combination of upfront, milestone and royalty payments; or an outright sale, which would see
a one-off payment to ValiRx.

Next Q&A should be due fairly soon.

Rightback, so sorry to hear that and for your lose. Wishing you all the best old buddy.

I am feeling more and more confident the more i delve into things. So a disease impact rate of 54.5% with no deaths at all on the trial is outstanding. So the trials began back in 2014. 6 years ago. Can i ask, does anyone know the average survival time of someone with late stage prostate cancer? If its a lot less than 6 years i think we have a very interesting drug in 201.

Nick, don't tell me John Smith is that absolute pleb Russell that used to be on the watsap group is it? haha makes complete sense!